Development of translational pharmacokinetic-pharmacodynamic models
about
Recent developments in using mechanistic cardiac modelling for drug safety evaluationModeling and Simulation Approaches for Cardiovascular Function and Their Role in Safety AssessmentImplementation of pharmacokinetic and pharmacodynamic strategies in early research phases of drug discovery and development at Novartis Institute of Biomedical ResearchAgent-based modeling: a systematic assessment of use cases and requirements for enhancing pharmaceutical research and development productivityMeta-modeling of methylprednisolone effects on glucose regulation in ratsEffect of disease states on α1 -adrenoceptor binding and signal transduction parameters in isolated perfused heart: quantification by pharmacokinetic-pharmacodynamic modelling.Pharmacokinetics of Anti-VEGF Agent Aflibercept in Cancer Predicted by Data-Driven, Molecular-Detailed Model.Translational pharmacokinetic-pharmacodynamic modelling; application to cardiovascular safety data for PF-00821385, a novel HIV agent.Comparison of two pharmacodynamic transduction models for the analysis of tumor therapeutic responses in model systemsTranslational PK-PD modelling of molecular target modulation for the AMPA receptor positive allosteric modulator Org 26576.Application of quantitative pharmacology in development of therapeutic monoclonal antibodiesStochastic modeling of systems mapping in pharmacogenomics.Tissue-level modeling of xenobiotic metabolism in liver: An emerging tool for enabling clinical translational researchThe development of a fully-integrated immune response model (FIRM) simulator of the immune response through integration of multiple subset models.Systems pharmacology approaches for optimization of antiangiogenic therapies: challenges and opportunities.Interspecies scaling of receptor-mediated pharmacokinetics and pharmacodynamics of type I interferons.Quantitative PK-PD model-based translational pharmacology of a novel kappa opioid receptor antagonist between rats and humans.Comparative performance of cell life span and cell transit models for describing erythropoietic drug effectsPharmacokinetics and pharmacodynamics of phase II drug metabolizing/antioxidant enzymes gene response by anticancer agent sulforaphane in rat lymphocytes.Translational pharmacokinetic-pharmacodynamic modeling from nonclinical to clinical development: a case study of anticancer drug, crizotinib.Effects of pharmacokinetic processes and varied dosing schedules on the dynamics of acquired resistance to erlotinib in EGFR-mutant lung cancer.Scaling pharmacodynamics from in vitro and preclinical animal studies to humans.Moving from basic toward systems pharmacodynamic models.Quantitative Systems Pharmacology: A Framework for Context.Application of pharmacokinetic and pharmacodynamic analysis to the development of liposomal formulations for oncology.Multiscale modeling in drug discovery and development: future opportunities and present challenges.Merging systems biology with pharmacodynamics.Utility of free and total target measurements as target engagement and efficacy biomarkers in biotherapeutic development--opportunities and challenges.Developing Exposure/Response Models for Anticancer Drug Treatment: Special ConsiderationsMulti-scale Modeling in Clinical Oncology: Opportunities and Barriers to Success.Model-based assessment of erlotinib effect in vitro measured by real-time cell analysis.Pharmacokinetic-pharmacodynamic modeling of the antihypertensive interaction between azilsartan medoxomil and chlorthalidone in spontaneously hypertensive rats.Enhancing value of clinical pharmacodynamics in oncology drug development: An alliance between quantitative pharmacology and translational science.Translational Modeling and Simulation in Supporting Early-Phase Clinical Development of New Drug: A Learn-Research-Confirm Process.Using network biology to bridge pharmacokinetics and pharmacodynamics in oncology.Translational mixed-effects PKPD modelling of recombinant human growth hormone - from hypophysectomized rat to patients.Quantifying and Communicating Uncertainty in Preclinical Human Dose-Prediction.A General Network Pharmacodynamic Model-Based Design Pipeline for Customized Cancer Therapy Applied to the VEGFR Pathway.Development of a new pre- and post-processing tool (SADAPT-TRAN) for nonlinear mixed-effects modeling in S-ADAPT.Modeling rejection immunity.
P2860
Q26764870-FDDE4BFE-D21F-430B-9808-90A5121C3BA0Q26801610-06DE2FD2-98F6-4DD4-BDED-F146A2FD7D42Q27024682-B735E6C2-11CD-4BFF-BE01-1E5F46302CB1Q27028010-B718D1CD-85D8-4D2E-926B-E3902BF62007Q28535673-F3996B19-C010-41BB-9FF4-C2781F61DC9AQ30317605-54AF15FC-A345-41CB-8A17-2EA688ACA122Q31037873-0E47A78B-5729-4ED0-82DC-C3143705C1D2Q33560293-70A4D79D-2A87-4DD9-B526-F7F7A916BF2FQ33611516-19E722E9-C69A-4B9C-9B78-550D1AD06102Q34190402-8AFB5060-934A-40F2-8E5E-AD33D51EC0C7Q34293689-2C04FB4C-3506-46C6-BCC1-0F8C153E4DC5Q34599933-7897CE31-9B20-4A83-A5C9-BE5D99370922Q34746268-DB7A2CCA-DF2E-4E6C-8D08-B57909491DA8Q35001424-D29E249C-1E51-49FD-9DA0-302AD71DD253Q35104052-A2345207-0B29-4BFC-9867-8F69010196BDQ35223673-F9348DE0-E2D5-4E58-B78E-E2E0FBB448B5Q35595776-6D148DB5-A0B4-43C2-B173-8C09A70092B9Q35595803-A6019FD2-467B-4AFC-8DDB-2EAA229E63A4Q36632235-8E951902-F854-4813-9D56-6C45E31A632AQ36910546-4C7C8862-B27C-495D-8FF0-3B26DEC37855Q36956272-5D3BFF0A-41DA-42D2-A10F-C013AA8A0AC1Q37055123-2A65AF13-8D2B-4F84-AFDC-2B59AC01E341Q37096317-D3C749FC-9BED-4C19-979E-CD809C8F9B1FQ37200950-B398F26B-B2CB-4AF9-9A80-C4A736BB99FCQ37689857-8649F046-27AB-453B-9F1D-A7759137BE5DQ37762442-D81D75CC-0573-4619-B4C2-F74DAAF4C26FQ37996185-0CAF5FED-1B2C-47CB-8407-15B24F0C1643Q38364466-A74F6E30-55D1-4D32-AF89-BF990BA9D7ADQ38557331-B06D488E-3A3F-43CC-8385-491313DEE6D7Q38888255-61E3EDA9-F39C-40AE-B7BD-5C6325B03639Q38893248-001E553F-AB01-4D1A-814D-BCD19DA26958Q38965224-01E452D0-6A13-4CF9-8B77-37532D1CBFB9Q38996431-7C409107-F45F-4F20-894C-EF7461494894Q39079388-CF21265E-ABA6-4863-8D58-32AFDE8C41B1Q39355451-6845749D-4423-43BA-B0F8-B876822D5426Q39963734-49C135B2-5F49-4023-8308-352215029876Q40606599-EF264B35-9D0F-4ADA-AFB6-5BD3CC09B663Q41906107-CDAAE3E7-2B2E-48C3-B2BB-D99EF03C187DQ41987074-ACC35133-23C1-4B11-B962-C424C11E7C84Q42113870-140DF2E9-A130-4C9D-BBD8-E1C3C095E341
P2860
Development of translational pharmacokinetic-pharmacodynamic models
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 26 March 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Development of translational pharmacokinetic-pharmacodynamic models
@en
Development of translational pharmacokinetic-pharmacodynamic models.
@nl
type
label
Development of translational pharmacokinetic-pharmacodynamic models
@en
Development of translational pharmacokinetic-pharmacodynamic models.
@nl
prefLabel
Development of translational pharmacokinetic-pharmacodynamic models
@en
Development of translational pharmacokinetic-pharmacodynamic models.
@nl
P2860
P356
P1476
Development of translational pharmacokinetic-pharmacodynamic models
@en
P2093
P2860
P304
P356
10.1038/CLPT.2008.52
P407
P577
2008-03-26T00:00:00Z